Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial

S. E. Straus, A. Wald, R. G. Kost, Robin McKenzie, A. G M Langenberg, P. Hohman, J. Lekstrom, E. Cox, M. Nakamura, R. Sekulovich, A. Izu, C. Dekker, L. Corey

Research output: Contribution to journalArticle

Abstract

To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4-14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoprotein-specific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.

Original languageEnglish (US)
Pages (from-to)1129-1134
Number of pages6
JournalJournal of Infectious Diseases
Volume176
Issue number5
StatePublished - 1997
Externally publishedYes

Fingerprint

Herpes Genitalis
Human Herpesvirus 2
Immunotherapy
Vaccines
Placebos
Recurrence
Glycoproteins
Vaccination
Neutralizing Antibodies
Disease Outbreaks
herpes simplex virus type 2 glycoprotein B
glycoprotein D-herpes simplex virus type 2
Referral and Consultation
Randomized Controlled Trials
Safety
Injections

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B : Results of a placebo-controlled vaccine trial. / Straus, S. E.; Wald, A.; Kost, R. G.; McKenzie, Robin; Langenberg, A. G M; Hohman, P.; Lekstrom, J.; Cox, E.; Nakamura, M.; Sekulovich, R.; Izu, A.; Dekker, C.; Corey, L.

In: Journal of Infectious Diseases, Vol. 176, No. 5, 1997, p. 1129-1134.

Research output: Contribution to journalArticle

Straus, SE, Wald, A, Kost, RG, McKenzie, R, Langenberg, AGM, Hohman, P, Lekstrom, J, Cox, E, Nakamura, M, Sekulovich, R, Izu, A, Dekker, C & Corey, L 1997, 'Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial', Journal of Infectious Diseases, vol. 176, no. 5, pp. 1129-1134.
Straus, S. E. ; Wald, A. ; Kost, R. G. ; McKenzie, Robin ; Langenberg, A. G M ; Hohman, P. ; Lekstrom, J. ; Cox, E. ; Nakamura, M. ; Sekulovich, R. ; Izu, A. ; Dekker, C. ; Corey, L. / Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B : Results of a placebo-controlled vaccine trial. In: Journal of Infectious Diseases. 1997 ; Vol. 176, No. 5. pp. 1129-1134.
@article{28395a1d07a444969b8cb961d055cf2c,
title = "Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial",
abstract = "To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4-14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoprotein-specific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.",
author = "Straus, {S. E.} and A. Wald and Kost, {R. G.} and Robin McKenzie and Langenberg, {A. G M} and P. Hohman and J. Lekstrom and E. Cox and M. Nakamura and R. Sekulovich and A. Izu and C. Dekker and L. Corey",
year = "1997",
language = "English (US)",
volume = "176",
pages = "1129--1134",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B

T2 - Results of a placebo-controlled vaccine trial

AU - Straus, S. E.

AU - Wald, A.

AU - Kost, R. G.

AU - McKenzie, Robin

AU - Langenberg, A. G M

AU - Hohman, P.

AU - Lekstrom, J.

AU - Cox, E.

AU - Nakamura, M.

AU - Sekulovich, R.

AU - Izu, A.

AU - Dekker, C.

AU - Corey, L.

PY - 1997

Y1 - 1997

N2 - To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4-14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoprotein-specific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.

AB - To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4-14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoprotein-specific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.

UR - http://www.scopus.com/inward/record.url?scp=16944362192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944362192&partnerID=8YFLogxK

M3 - Article

C2 - 9359709

AN - SCOPUS:16944362192

VL - 176

SP - 1129

EP - 1134

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -